Insider · CIK 0001273351
Edward Carr
Files at DNTH (Dianthus Therapeutics, Inc. /DE/). First filing Mar 13, 2026, latest Sep 18, 2026.
In brief
Edward Carr files SEC Form 4 as officer at DNTH (Dianthus Therapeutics, Inc. /DE/). Since Mar 13, 2026, Edward Carr has reported 0 open-market buys worth $0 and 2 open-market sells worth $5.6M, the latest filed on Sep 18, 2026.
A track record needs three past buys with six months of prices behind them; Edward Carr has 0, so none is measured yet.
The newest scored trade: sold $2.0M of DNTH on Sep 17, 2026, filed Sep 18, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $5.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | $2.0M 20,000 shares | -100% | - | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | $3.6M 43,682 shares | -100% | +441% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. | 20,000 0.04% of outstanding | $2.0M | Sep 17, 2026 | none |
| Mar 12, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 43,682 0.10% of outstanding | $3.7M | Mar 12, 2026 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +20,000 | $17.88 | $358k | 20,000 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -7,928 | $100.43 | $796k | 12,072 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -6,771 | $101.37 | $686k | 5,301 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -3,501 | $102.39 | $358k | 1,800 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -1,100 | $103.20 | $114k | 700 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -700 | $104.39 | $73k | 0 | 25 d ago |
| Sep 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 43,818 | 25 d ago |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +16,182 | $17.88 | $289k | 16,182 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +17,500 | $22.07 | $386k | 33,682 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +10,000 | $21.77 | $218k | 43,682 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -15,852 | $80.71 | $1.3M | 27,830 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -23,465 | $81.75 | $1.9M | 4,365 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -3,865 | $82.66 | $319k | 500 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -200 | $83.38 | $17k | 300 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -300 | $85.53 | $26k | 0 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,182 | $0.00 | $0 | 63,818 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 42,500 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 50,000 | Mar 13, 2026 |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 4, 2026 |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 4, 2025 |
Questions about Edward Carr
Answered from the filings on this page, as of the latest one.
Is Edward Carr buying or selling?
In the last 12 months Edward Carr reported 0 open-market buys worth $0 and 2 open-market sells worth $5.6M on SEC Form 4; the latest was sold $2.0M of DNTH on Sep 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Edward Carr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Edward Carr has 0.
Where does Edward Carr file Form 4?
Edward Carr has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/) as CHIEF ACCOUNTING OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.